- Conditions: Heart Failure; Endothelium
Intervention: Drug: Urocortin 2, Urocortin 3 and Substance P
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Not yet recruiting - verified May 2012 - Condition: Cardiovascular Disease
Intervention:
Sponsors: Queen Mary University of London; Queen Mary University of London; King's College London
Not yet recruiting - verified April 2012 - Condition: Cardiovascular Function
Intervention: Biological: Typhoid vaccine
Sponsors: Queen Mary University of London; Queen Mary University of London
Recruiting - verified April 2012 - Condition: Emergency Contraception
Intervention: Drug: ellaOne
Sponsors: HRA Pharma; HRA Pharma
Recruiting - verified March 2012 - Condition: Emergency Contraception
Interventions: Drug: Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon); Drug: placebo + ethinylestradiol/levonorgestrel
Sponsors: HRA Pharma; HRA Pharma
Recruiting - verified March 2012 - Condition: HIV Related Neurocognitive Impairment
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir; Drug: Telaprevir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; PENTA Foundation
Recruiting - verified March 2012 - Conditions: Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus
Interventions: Drug: Darunavir; Drug: Ritonavir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: AFQ056; Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Fragile X Syndrome
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Psoriasis
Intervention:
Sponsors: Abbott; Abbott; pH Associates
Recruiting - verified February 2012 - Condition: HIV
Interventions: Drug: Atazanavir Sulphate; Drug: Ritonavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: HIV Infection
Interventions: Drug: Efavirenz; Drug: Efavirenz
Sponsors: Kirby Institute; Kirby Institute; Chelsea and Westminster NHS Foundation Trust
Recruiting - verified February 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: AFQ056; Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention: Drug: Hydroxychloroquine
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified December 2011 - Conditions: Male Erectile Disorder; Prostate Cancer; Therapy-related Toxicity; Urinary Incontinence
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: multiparametric magnetic resonance imaging; Procedure: quality-of-life assessment; Procedure: transperineal prostate biopsy; Procedure: transrectal prostate biopsy
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified November 2010 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: HIV; AIDS; Indicator Diseases/Indicator Conditions
Interventions: Other: HIV test (serological or salivary); Other: Interview
Sponsors: Chelsea and Westminster NHS Foundation Trust; Chelsea and Westminster NHS Foundation Trust; HIV in Europe (Co-Sponsor)
Recruiting - verified October 2009 - Condition: Antiretroviral Therapy in HIV-1 Infected Children
Interventions: Drug: Kaletra dosed once daily; Drug: kaletra dosed twice daily
Sponsors: PENTA Foundation; PENTA Foundation; Medical Research Council; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting - verified February 2012 - Condition: HIV-1 Infections
Interventions: Biological: ChAdV63.HIVconsv low dose.; Biological: ChAdV63.HIVconsv high dose.; Biological: pSG2.HIVconsv; Biological: MVA.HIVconsv; Other: Placebo
Sponsors: University of Oxford; University of Oxford
Recruiting - verified February 2012 - Condition: Contraception
Interventions: Drug: ellaOne® (ulipristal acetate); Drug: ellaOne® (ulipristal acetate)
Sponsors: HRA Pharma; HRA Pharma
Recruiting - verified March 2012 - Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Prostate Cancer; Sexual Dysfunction
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified May 2011 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Conditions: Male Hypogonadism; Androgen Deficiency; Testosterone Deficiency
Intervention: Other: Standard of Care
Sponsors: New England Research Institutes; New England Research Institutes; Bayer
Recruiting - verified July 2011 - Condition: HIV Infections
Intervention:
Sponsors: Radboud University; Radboud University; PENTA Foundation; Merck; Bristol-Myers Squibb; CIHR Canadian HIV Trials Network
Recruiting - verified October 2011 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: carmustine; Drug: cyclophosphamide; Drug: cytarabine; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: etoposide phosphate; Drug: ifosfamide; Drug: melphalan; Drug: prednisolone; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Martin-Luther-Universität Halle-Wittenberg
Recruiting - verified June 2007 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012
 |
Join Clinical Trials for Sexual Diseases in the United Kingdom |
